Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [142]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Research works printed but not linked: 3
- D. Pardoll, Nature411, 1010 (2001).
- Y. Naito et al., Cancer Res.58, 3491 (1998).
- We thank A. Rodi and M. Pelegrin for expert technical assistance; I. Gresser for helpful comments and critical review of the manuscript; and D. Frucht C. Anderson and T. Pokrovska for critically reading the manuscript. Supported by the Association pour la Recherche sur le Cancer (ARC) through the Alliance pour la Recherche sur le Cancer network (ARECA) INSERM Action Concertée Incitative ACI IMPBio Université Paris-Descartes Paris 5 and the Austrian Federal Ministry of Education Science and Culture (GBN-AU project Bioinformatics Integration Network).
Cited by
Items 501–600 of 1,043
Chang, L.-Y., Lin, Y.-C., Mahalingam, J., Huang, C.-T., Chen, T.-W., Kang, C.-W., Peng, H.-M., Chu, Y.-Y., Chiang, J.-M., Dutta, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2493 · Cited by 232
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Melcher, A., Parato, K., Rooney, C. M., & Bell, J. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.65 · Cited by 232
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer
Masugi, Y., Nishihara, R., Yang, J., Mima, K., da Silva, A., Shi, Y., Inamura, K., Cao, Y., Song, M., Nowak, J. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311421 · Cited by 231
Selby, M. J., Engelhardt, J. J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K., Yao, D., Quigley, M., Valle, J., Wang, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161779 · Cited by 231
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 229
Fisher, D. T., Chen, Q., Skitzki, J. J., Muhitch, J. B., Zhou, L., Appenheimer, M. M., Vardam, T. D., Weis, E. L., Passanese, J., Wang, W.-C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44952 · Cited by 229
Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000340 · Cited by 228
“Based on preliminary translational observations, our work raised the possibility that AZD6738 might be a potential synergistic modality for radioimmunotherapy in HCC. Remark-edly, this study provides a basis for future clinical human studies into the treatment of HCC.”
Waniczek, D., Lorenc, Z., Śnietura, M., Wesecki, M., Kopec, A., & Muc-Wierzgoń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0463-9 · Cited by 228
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
de Jong, R. A., Leffers, N., Boezen, H. M., ten Hoor, K. A., van der Zee, A. G. J., Hollema, H., & Nijman, H. W. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.022 · Cited by 228
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Hakansson, L. G., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 228
Self-citationImmune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
Engelhard, V. H., Rodriguez, A. B., Mauldin, I. S., Woods, A. N., Peske, J. D., & Slingluff, C. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701269 · Cited by 228
Dahlin, A. M., Henriksson, M. L., Van Guelpen, B., Stenling, R., Öberg, Å., Rutegård, J., & Palmqvist, R. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.234 · Cited by 228
Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients
Diehl, F., Schmidt, K., Durkee, K. H., Moore, K. J., Goodman, S. N., Shuber, A. P., Kinzler, K. W., & Vogelstein, B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.039 · Cited by 228
Hennequin, A., Derangère, V., Boidot, R., Apetoh, L., Vincent, J., Orry, D., Fraisse, J., Causeret, S., Martin, F., Arnould, L., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1054598 · Cited by 226
Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits
Galili, U. (2013) · Immunology · doi:10.1111/imm.12110 · Cited by 225
Cassetta, L., Baekkevold, E. S., Brandau, S., Bujko, A., Cassatella, M. A., Dorhoi, A., Krieg, C., Lin, A., Loré, K., Marini, O., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02302-2 · Cited by 224
Barua, S., Fang, P., Sharma, A., Fujimoto, J., Wistuba, I., Rao, A. U. K., & Lin, S. H. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.022 · Cited by 223
Perforin: structure, function, and role in human immunopathology
Voskoboinik, I., Dunstone, M. A., Baran, K., Whisstock, J. C., & Trapani, J. A. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00896.x · Cited by 223
Tumor immunosurveillance in human cancers
Mlecnik, B., Bindea, G., Pagès, F., & Galon, J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9270-7 · Cited by 223
Self-citationMlecnik, B., Bindea, G., Angell, H. K., Sasso, M. S., Obenauf, A. C., Fredriksen, T., Lafontaine, L., Bilocq, A. M., Kirilovsky, A., Tosolini, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007240 · Cited by 223
Self-citationCurrent Status and Future Directions
Ito, F., & Chang, A. E. (2013) · Cited by 223
Two-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
Ge, P., Wang, W., Li, L., Zhang, G., Gao, Z., Tang, Z., Dang, X., & Wu, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109228 · Cited by 222
Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer
Faget, J., Groeneveld, S., Boivin, G., Sankar, M., Zangger, N., Garcia, M., Guex, N., Zlobec, I., Steiner, L., Piersigilli, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.052 · Cited by 222
Stramer, B. M., Zieske, J. D., Jung, J.-C., Austin, J. S., & Fini, M. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1188 · Cited by 221
The role of cytokines in T‐cell memory in health and disease
Raeber, M. E., Zurbuchen, Y., Impellizzieri, D., & Boyman, O. (2018) · Immunological Reviews · doi:10.1111/imr.12644 · Cited by 221
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Wilcox, R. A., Feldman, A. L., Wada, D. A., Yang, Z.-Z., Comfere, N. I., Dong, H., Kwon, E. D., Novak, A. J., Markovic, S. N., Pittelkow, M. R., et al. (2009) · Blood · doi:10.1182/blood-2009-04-216671 · Cited by 221
CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome
Huang, Y., Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Hunborg, P., Varvares, M. A., Hoft, D. F., Hsueh, E. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3958 · Cited by 220
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 219
The paradox of Th17 cell functions in tumor immunity
Asadzadeh, Z., Mohammadi, H., Safarzadeh, E., Hemmatzadeh, M., Mahdian-shakib, A., Jadidi-Niaragh, F., Azizi, G., & Baradaran, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.015 · Cited by 219
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26974-6 · Cited by 218
Tumor-Infiltrating Lymphocytes, Crohn’s-Like Lymphoid Reaction, and Survival From Colorectal Cancer
Rozek, L. S., Schmit, S. L., Greenson, J. K., Tomsho, L. P., Rennert, H. S., Rennert, G., & Gruber, S. B. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw027 · Cited by 218
Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy
Chew, V., Toh, H. C., & Abastado, J.-P. (2012) · Journal of Oncology · doi:10.1155/2012/608406 · Cited by 218
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
Mirzaei, H. R., Rodriguez, A., Shepphird, J., Brown, C. E., & Badie, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01850 · Cited by 217
Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
Kwa, M. J., & Adams, S. (2018) · Cancer · doi:10.1002/cncr.31272 · Cited by 217
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
Heindl, A., Nawaz, S., & Yuan, Y. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2014.155 · Cited by 216
Cytokine-Induced Modulation of Colorectal Cancer
Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00096 · Cited by 216
Rajput, A. B., Turbin, D. A., Cheang, M. C., Voduc, D. K., Leung, S., Gelmon, K. A., Gilks, C. B., & Huntsman, D. G. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9546-3 · Cited by 216
Chemokines in cancer related inflammation
Allavena, P., Germano, G., Marchesi, F., & Mantovani, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.11.013 · Cited by 215
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 215
High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas
Le Gouvello, S., Bastuji-Garin, S., Aloulou, N., Mansour, H., Chaumette, M.-T., Berrehar, F., Seikour, A., Charachon, A., Karoui, M., Leroy, K., et al. (2008) · Gut · doi:10.1136/gut.2007.123794 · Cited by 214
Cell-Type Enrichment Analysis of Bulk Transcriptomes Using xCell
Aran, D. (2020) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0327-7_19 · Cited by 214
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
Draube, A., Klein-González, N., Mattheus, S., Brillant, C., Hellmich, M., Engert, A., & von Bergwelt-Baildon, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018801 · Cited by 214
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Self-citationPrinciples of adoptive T cell therapy in cancer
Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M., & Svane, I. M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 213
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer
Pinto, M. L., Rios, E., Durães, C., Ribeiro, R., Machado, J. C., Mantovani, A., Barbosa, M. A., Carneiro, F., & Oliveira, M. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01875 · Cited by 213
Heterogeneity in immune responses: from populations to single cells
Satija, R., & Shalek, A. K. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.03.004 · Cited by 213
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
Becker, A., Sells, B., Haque, S., & Chakravarti, A. (2021) · Cancers · doi:10.3390/cancers13040761 · Cited by 212
STAT3 activation: A key factor in tumor immunoescape
Rébé, C., Végran, F., Berger, H., & Ghiringhelli, F. (2013) · JAK-STAT · doi:10.4161/jkst.23010 · Cited by 212
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., Chang, E. C., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01916-x · Cited by 212
Self-citationA guide to artificial intelligence for cancer researchers
Perez-Lopez, R., Ghaffari Laleh, N., Mahmood, F., & Kather, J. N. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00694-7 · Cited by 211
Exercise-Dependent Regulation of NK Cells in Cancer Protection
Idorn, M., & Hojman, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.007 · Cited by 211
Mlecnik, B., Bifulco, C., Bindea, G., Marliot, F., Lugli, A., Lee, J. J., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03205 · Cited by 210
Self-citationPerrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 210
Polarized immune responses differentially regulate cancer development
Johansson, M., DeNardo, D. G., & Coussens, L. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00600.x · Cited by 209
“Recently, CD3(1) T-cell densities within colorectal cancer biopsies were found to be a better predictor of patient survival than standard histopathological staging methods (78).”
Suzuki, K., Kadota, K., Sima, C. S., Nitadori, J.-I., Rusch, V. W., Travis, W. D., Sadelain, M., & Adusumilli, P. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2052 · Cited by 209
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K., & Beatty, G. L. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.2 · Cited by 208
Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Elliott, L. A., Doherty, G. A., Sheahan, K., & Ryan, E. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00086 · Cited by 208
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology
Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., & Gallagher, W. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2902 · Cited by 208
High endothelial venules (HEVs) in immunity, inflammation and cancer
Blanchard, L., & Girard, J.-P. (2021) · Angiogenesis · doi:10.1007/s10456-021-09792-8 · Cited by 207
Zhang, H., Liu, H., Shen, Z., Lin, C., Wang, X., Qin, J., Qin, X., Xu, J., & Sun, Y. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002058 · Cited by 207
Alexe, G., Dalgin, G. S., Scanfeld, D., Tamayo, P., Mesirov, J. P., DeLisi, C., Harris, L., Barnard, N., Martel, M., Levine, A. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0539 · Cited by 207
Yu, J. W., Bhattacharya, S., Yanamandra, N., Kilian, D., Shi, H., Yadavilli, S., Katlinskaya, Y., Kaczynski, H., Conner, M., Benson, W., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0206223 · Cited by 206
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
The immune network in pancreatic cancer development and progression
Wörmann, S. M., Diakopoulos, K. N., Lesina, M., & Algül, H. (2014) · Oncogene · doi:10.1038/onc.2013.257 · Cited by 205
Bluemel, C., Hausmann, S., Fluhr, P., Sriskandarajah, M., Stallcup, W. B., Baeuerle, P. A., & Kufer, P. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0844-y · Cited by 205
B cells and cancer: To B or not to B?
Fridman, W. H., Petitprez, F., Meylan, M., Chen, T. W.-W., Sun, C.-M., Roumenina, L. T., & Sautès-Fridman, C. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200851 · Cited by 204
Self-citationImmune responses to malignancies
Whiteside, T. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.045 · Cited by 204
Spatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 203
Chao, B., Ju, X., Zhang, L., Xu, X., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00766 · Cited by 203
Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.004 · Cited by 203
Self-citationImmune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Thomas, R., Al-Khadairi, G., & Decock, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600573 · Cited by 202
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Nagorsen, D., & Baeuerle, P. A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.010 · Cited by 202
Bertini, I., Cacciatore, S., Jensen, B. V., Schou, J. V., Johansen, J. S., Kruhøffer, M., Luchinat, C., Nielsen, D. L., & Turano, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1543 · Cited by 202
Chen, Y., Wang, D., Li, Y., Qi, L., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 201
Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel
Jin, H., Wan, C., Zou, Z., Zhao, G., Zhang, L., Geng, Y., Chen, T., Huang, A., Jiang, F., Feng, J.-P., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08148 · Cited by 201
Rutledge, W. C., Kong, J., Gao, J., Gutman, D. A., Cooper, L. A. D., Appin, C., Park, Y., Scarpace, L., Mikkelsen, T., Cohen, M. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0551 · Cited by 200
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“Furthermore, patients with high intratumoral expression of the T cell marker CD3 had improved disease-free survival compared to patients with low levels of CD3 (34).”
The speed of change: towards a discontinuity theory of immunity?
Pradeu, T., Jaeger, S., & Vivier, E. (2013) · Nature Reviews Immunology · doi:10.1038/nri3521 · Cited by 199
Tumor immunoediting and immunosculpting pathways to cancer progression
Reiman, J. M., Kmieciak, M., Manjili, M. H., & Knutson, K. L. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.009 · Cited by 199
Hanus, M., Parada-Venegas, D., Landskron, G., Wielandt, A. M., Hurtado, C., Alvarez, K., Hermoso, M. A., López-Köstner, F., & De la Fuente, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612826 · Cited by 199
Prognostic impact of B-cell density in cutaneous melanoma
Ladányi, A., Kiss, J., Mohos, A., Somlai, B., Liszkay, G., Gilde, K., Fejős, Z., Gaudi, I., Dobos, J., & Tímár, J. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1071-x · Cited by 199
Ranki, T., Pesonen, S., Hemminki, A., Partanen, K., Kairemo, K., Alanko, T., Lundin, J., Linder, N., Turkki, R., Ristimäki, A., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0121-5 · Cited by 199
Näsman, A., Romanitan, M., Nordfors, C., Grün, N., Johansson, H., Hammarstedt, L., Marklund, L., Munck-Wikland, E., Dalianis, T., & Ramqvist, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038711 · Cited by 199
Fucikova, J., Becht, E., Iribarren, K., Goc, J., Remark, R., Damotte, D., Alifano, M., Devi, P., Biton, J., Germain, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1142 · Cited by 199
Self-citationTransforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor Microenvironment
Achyut, B. R., & Yang, L. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.048 · Cited by 199
Suppression, subversion and escape: the role of regulatory T cells in cancer progression
Oleinika, K., Nibbs, R. J., Graham, G. J., & Fraser, A. R. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04657.x · Cited by 198
The Role of Complement in Tumor Growth
Pio, R., Corrales, L., & Lambris, J. D. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5915-6_11 · Cited by 198
Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
Oliveira, A. F., Bretes, L., & Furtado, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00396 · Cited by 198
The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
Huynh, J., Etemadi, N., Hollande, F., Ernst, M., & Buchert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.001 · Cited by 198
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Corrales, L., & Gajewski, T. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1362 · Cited by 197
Role of Stat3 in suppressing anti-tumor immunity
Kortylewski, M., & Yu, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.010 · Cited by 196
Metadata
- Authors
- Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Pagès, F.
- Affiliations
- INSERM U 255, Paris, 75006 France; Université Paris-Descartes Paris 5, Faculté de Médecine, Paris, 75006 France; and Université Pierre et Marie Curie Paris 6, Institut des Cordeliers, Paris, 75006 France.
- Inserm (FR)
- ORCID
- Venue
- Science
- Published
- 2006-09-29
- Volume
- 313
- Issue
- 5795
- Pages
- 1960-1964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2142300779
- Cited by
- 6,516
- References
- 31
- Citations by year
- 2026: 237 · 2025: 278 · 2024: 329 · 2023: 444 · 2022: 451 · 2021: 574 · 2020: 524 · 2019: 433 · 2018: 447 · 2017: 405 · 2016: 394 · 2015: 380 · 2014: 268 · 2013: 282 · 2012: 237
- FWCI
- 70.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, tumor-infiltrating immune cells, adaptive immune response, prognostic factors, patient survival, tumor immune microenvironment, gene expression profiling, cancer immunotherapy
- MeSH terms
- Female, Humans, Immunohistochemistry, Immunologic Memory, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Cohort Studies, Survival Analysis, Polymerase Chain Reaction, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD3 Complex, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Th1 Cells, Disease Progression, Disease-Free Survival, Lymphocyte Count, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.